We hypothesize that these compounds can modify the CXCL12/CXCR4/CXCR7 pathway commonly involved in regulation of hematopoietic cell trafficking suggesting potential additional benefits of these compounds for CAD patients. The gene discussed is CXCR4; the disease is coronary artery disorder.